Skip to content
BioalmanacPeptide reference
Account
Menu

Stack

Semaglutide and Cagrilintide

A GLP-1 agonist with an amylin analogue. The one combination in this category being developed as an actual drug, and the reason it earns a proper write-up.

Semaglutide acts on the GLP-1 receptor; cagrilintide is a long-acting amylin analogue. They suppress appetite through different signals, and the combination is in late-stage clinical development as a single product.

That makes this unusual among stacks on this site: the combination itself is being trialled, rather than being an inference from two separate literatures. Published phase 2 results reported greater weight loss than either component alone.

The titration matters more here than in any other stack. Both components are escalated slowly, and the gastrointestinal effects that cause people to stop are almost entirely a function of going up too fast.

The schedule

Written and cited by us

20 weeks. Doses are what sources describe rather than what we advise — where a source gave a range we show the range instead of choosing a number inside it.

Each compound in Semaglutide and Cagrilintide, with its dose and schedule.
CompoundDoseHow oftenWeeks
SemaglutideApprovedGLP-1 receptor agonist. Titrated over the first sixteen weeks.0.25 mg–2.4 mgWeekly · MonStandard escalation is 0.25 mg weekly for four weeks, then 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals.1–20
CagrilintideClinical trialsAmylin analogue. Escalated on the same schedule as the GLP-1.0.25 mg–2.4 mgWeekly · MonTrials escalated both components together on a matched schedule.1–20

Start this stack

Things worth knowing

  • Escalate slowly. Nausea, vomiting and diarrhoea are the dose-limiting effects and are worst in the week after each increase.
  • Both components delay gastric emptying, and the combination does so more than either alone. Anyone with gastroparesis should avoid it.
  • Stop before any procedure requiring sedation, and tell the anaesthetist. Delayed emptying is an aspiration risk.
  • Semaglutide carries a thyroid C-cell tumour warning from rodent studies. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
  • Rapid weight loss increases gallstone risk, and combining two appetite suppressants makes rapid loss more likely.

Related

Instead of bothSemaglutide vs cagrilintideTwo different satiety pathways, usually discussed as a pair rather than a choice. One is an approved drug on its own; the other is mostly studied alongside it.Another stackA GLP-1 with 5-Amino-1MQAn incretin agonist doing the established work, with an oral NNMT inhibitor added on a mechanism that has never been tested in a person. One half of this has phase 3 trials; the other half has mice.Another stackRetatrutide with MOTS-cA triple incretin agonist next to a mitochondrial peptide, on the argument that losing weight fast is easier than losing it well. The second half has never finished a human trial.

Questions

Is this the same as the combination in trials?
The pairing is the same idea, an incretin agonist with an amylin analogue, and it has been studied as a fixed-dose product. What people run is not that product: the two are separate vials at doses they choose, which is a different thing from the co-formulation the trials tested.
Why add cagrilintide to a GLP-1 at all?
Amylin analogues act on satiety by a different pathway from GLP-1, so the argument is additive appetite suppression rather than a bigger dose of the same mechanism. In the trial programme the combination did outperform semaglutide alone.
Do the side effects add up too?
Gastrointestinal effects are the dose-limiting problem for both compounds and they are the reason both are titrated slowly. Raising two of them at once is how people end up unable to tell which is responsible, and unable to reduce the right one.

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.